Global Refractory Multiple Myeloma Treatment Market

Refractory Multiple Myeloma Treatment Comprehensive Study by Type (Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib), Cytotoxic agents, High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT), Allogeneic Stem Cell Transplantation), Distribution Channel (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others), Drug Class (Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, Others) Players and Region - Global Market Outlook to 2030

Refractory Multiple Myeloma Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Refractory Multiple Myeloma Treatment
Multiple myeloma is a malignant plasma cell disease that mostly affects secondary organs such as the bone, kidney, and bone marrow, as well as immune and neurologic dysfunction. Multiple myeloma is a clonal plasma cell cancer caused by complex interactions between bone marrow stromal cells, malignant progenitor cells, and the microenvironment of the bone marrow. Refractory multiple myeloma is characterized as a disease that is progressing or non-responsive to therapy, or is progressing or non-responsive within sixty days of the last treatment in patients with a poor response. The increasing prevalence of multiple myeloma, advancement in research and development for innovative therapeutics for refractory multiple myeloma treatment, and the introduction of monoclonal antibodies for refractory multiple myeloma treatment are some of the factors driving the growth of the refractory multiple myeloma treatment market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The Refractory Multiple Myeloma Treatment treatment market is expected to continue growing, driven by the development of new targeted therapies, personalized medicine approaches, and the increasing need for effective treatments for this aggressive disease. Competition will remain fierce, with established players facing pressure from new entrants and the evolving treatment landscape. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Refractory Multiple Myeloma Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (Unite States), Amgen Inc. (United States) and ONO PHARMACEUTICAL CO., LTD. (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Janssen Pharmaceuticals, Inc. (United States), AbbVie Inc (United States) and Sanofi (France).

Segmentation Overview
AMA Research has segmented the market of Global Refractory Multiple Myeloma Treatment market by Type (Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib), Cytotoxic agents, High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT) and Allogeneic Stem Cell Transplantation) and Region.



On the basis of geography, the market of Refractory Multiple Myeloma Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Refractory Multiple Myeloma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Proteasome Inhibitor will boost the Refractory Multiple Myeloma Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing use of online platforms and social media to reach wider audiences and educate patients and healthcare professionals.

Market Growth Drivers:
Increased Prevalence of numerous forms of Blood Cancers and Increased need for efficient and effective treatments or Rare Diseases

Challenges:
Lack of Effective Treatments in Certain Countries and Lack of Awareness Among People

Restraints:
Lack of R&D as it is a rare disease and High Cost of Treatment

Opportunities:
Advancement in Research and Development for Innovative Therapeutics

Market Leaders and their expansionary development strategies
In December 2023, AbbVie joins forces with the American Cancer Society on improving access to care for RRMM patients. This partnership focuses on reducing disparities in RRMM treatment and ensuring equitable access to new therapies.
In November 2023, AbbVie unveils elnetoligide (Plenaxis). This novel oral immunomodulatory drug, approved for use with dexamethasone in newly diagnosed or RRMM patients, offers a new treatment option with potentially fewer side effects.


Key Target Audience
Pharmaceutical Companies, Suppliers, Medical Research Companies, Governmental & Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
  • Cytotoxic agents
  • High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
  • Allogeneic Stem Cell Transplantation
By Distribution Channel
  • Hospitals
  • Cancer Institutes
  • Ambulatory Surgical Centers
  • Others

By Drug Class
  • Proteasome Inhibitor
  • Anti-CD38 Monoclonal Antibody
  • Alkylating Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of numerous forms of Blood Cancers
      • 3.2.2. Increased need for efficient and effective treatments or Rare Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Effective Treatments in Certain Countries
      • 3.3.2. Lack of Awareness Among People
    • 3.4. Market Trends
      • 3.4.1. Increasing use of online platforms and social media to reach wider audiences and educate patients and healthcare professionals.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Refractory Multiple Myeloma Treatment, by Type, Distribution Channel, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Refractory Multiple Myeloma Treatment (Value)
      • 5.2.1. Global Refractory Multiple Myeloma Treatment by: Type (Value)
        • 5.2.1.1. Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
        • 5.2.1.2. Cytotoxic agents
        • 5.2.1.3. High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
        • 5.2.1.4. Allogeneic Stem Cell Transplantation
      • 5.2.2. Global Refractory Multiple Myeloma Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Cancer Institutes
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Refractory Multiple Myeloma Treatment by: Drug Class (Value)
        • 5.2.3.1. Proteasome Inhibitor
        • 5.2.3.2. Anti-CD38 Monoclonal Antibody
        • 5.2.3.3. Alkylating Agents
        • 5.2.3.4. Others
      • 5.2.4. Global Refractory Multiple Myeloma Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Refractory Multiple Myeloma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol Myers Squibb Company (Unite States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ONO PHARMACEUTICAL CO., LTD. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Refractory Multiple Myeloma Treatment Sale, by Type, Distribution Channel, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Refractory Multiple Myeloma Treatment (Value)
      • 7.2.1. Global Refractory Multiple Myeloma Treatment by: Type (Value)
        • 7.2.1.1. Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
        • 7.2.1.2. Cytotoxic agents
        • 7.2.1.3. High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
        • 7.2.1.4. Allogeneic Stem Cell Transplantation
      • 7.2.2. Global Refractory Multiple Myeloma Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Cancer Institutes
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Refractory Multiple Myeloma Treatment by: Drug Class (Value)
        • 7.2.3.1. Proteasome Inhibitor
        • 7.2.3.2. Anti-CD38 Monoclonal Antibody
        • 7.2.3.3. Alkylating Agents
        • 7.2.3.4. Others
      • 7.2.4. Global Refractory Multiple Myeloma Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Refractory Multiple Myeloma Treatment: by Type(USD Million)
  • Table 2. Refractory Multiple Myeloma Treatment Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib) , by Region USD Million (2018-2023)
  • Table 3. Refractory Multiple Myeloma Treatment Cytotoxic agents , by Region USD Million (2018-2023)
  • Table 4. Refractory Multiple Myeloma Treatment High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT) , by Region USD Million (2018-2023)
  • Table 5. Refractory Multiple Myeloma Treatment Allogeneic Stem Cell Transplantation , by Region USD Million (2018-2023)
  • Table 6. Refractory Multiple Myeloma Treatment: by Distribution Channel(USD Million)
  • Table 7. Refractory Multiple Myeloma Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 8. Refractory Multiple Myeloma Treatment Cancer Institutes , by Region USD Million (2018-2023)
  • Table 9. Refractory Multiple Myeloma Treatment Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 10. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2018-2023)
  • Table 11. Refractory Multiple Myeloma Treatment: by Drug Class(USD Million)
  • Table 12. Refractory Multiple Myeloma Treatment Proteasome Inhibitor , by Region USD Million (2018-2023)
  • Table 13. Refractory Multiple Myeloma Treatment Anti-CD38 Monoclonal Antibody , by Region USD Million (2018-2023)
  • Table 14. Refractory Multiple Myeloma Treatment Alkylating Agents , by Region USD Million (2018-2023)
  • Table 15. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2018-2023)
  • Table 16. South America Refractory Multiple Myeloma Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 18. South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 19. South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 20. Brazil Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 21. Brazil Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 23. Argentina Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 24. Argentina Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 25. Argentina Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 26. Rest of South America Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 28. Rest of South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 29. Asia Pacific Refractory Multiple Myeloma Treatment, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 32. Asia Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 33. China Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 34. China Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 35. China Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 36. Japan Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 37. Japan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 38. Japan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 39. India Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 40. India Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 41. India Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 42. South Korea Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 43. South Korea Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 44. South Korea Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 45. Taiwan Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 46. Taiwan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 47. Taiwan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 48. Australia Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 49. Australia Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 50. Australia Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 54. Europe Refractory Multiple Myeloma Treatment, by Country USD Million (2018-2023)
  • Table 55. Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 56. Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 57. Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 58. Germany Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 59. Germany Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 60. Germany Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 61. France Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 62. France Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 63. France Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 64. Italy Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 65. Italy Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 66. Italy Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 67. United Kingdom Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 69. United Kingdom Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 70. Netherlands Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 71. Netherlands Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 72. Netherlands Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 73. Rest of Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 75. Rest of Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 76. MEA Refractory Multiple Myeloma Treatment, by Country USD Million (2018-2023)
  • Table 77. MEA Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 78. MEA Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 79. MEA Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 80. Middle East Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 81. Middle East Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 82. Middle East Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 83. Africa Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 84. Africa Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 85. Africa Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 86. North America Refractory Multiple Myeloma Treatment, by Country USD Million (2018-2023)
  • Table 87. North America Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 88. North America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 89. North America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 90. United States Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 91. United States Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 92. United States Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 93. Canada Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 94. Canada Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 95. Canada Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 96. Mexico Refractory Multiple Myeloma Treatment, by Type USD Million (2018-2023)
  • Table 97. Mexico Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 98. Mexico Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Refractory Multiple Myeloma Treatment: by Type(USD Million)
  • Table 107. Refractory Multiple Myeloma Treatment Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib) , by Region USD Million (2025-2030)
  • Table 108. Refractory Multiple Myeloma Treatment Cytotoxic agents , by Region USD Million (2025-2030)
  • Table 109. Refractory Multiple Myeloma Treatment High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT) , by Region USD Million (2025-2030)
  • Table 110. Refractory Multiple Myeloma Treatment Allogeneic Stem Cell Transplantation , by Region USD Million (2025-2030)
  • Table 111. Refractory Multiple Myeloma Treatment: by Distribution Channel(USD Million)
  • Table 112. Refractory Multiple Myeloma Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 113. Refractory Multiple Myeloma Treatment Cancer Institutes , by Region USD Million (2025-2030)
  • Table 114. Refractory Multiple Myeloma Treatment Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 115. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2025-2030)
  • Table 116. Refractory Multiple Myeloma Treatment: by Drug Class(USD Million)
  • Table 117. Refractory Multiple Myeloma Treatment Proteasome Inhibitor , by Region USD Million (2025-2030)
  • Table 118. Refractory Multiple Myeloma Treatment Anti-CD38 Monoclonal Antibody , by Region USD Million (2025-2030)
  • Table 119. Refractory Multiple Myeloma Treatment Alkylating Agents , by Region USD Million (2025-2030)
  • Table 120. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2025-2030)
  • Table 121. South America Refractory Multiple Myeloma Treatment, by Country USD Million (2025-2030)
  • Table 122. South America Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 123. South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 124. South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 125. Brazil Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 126. Brazil Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 127. Brazil Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 128. Argentina Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 129. Argentina Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 130. Argentina Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 131. Rest of South America Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 133. Rest of South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 134. Asia Pacific Refractory Multiple Myeloma Treatment, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 137. Asia Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 138. China Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 139. China Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 140. China Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 141. Japan Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 142. Japan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 143. Japan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 144. India Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 145. India Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 146. India Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 147. South Korea Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 148. South Korea Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 149. South Korea Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 150. Taiwan Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 151. Taiwan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 152. Taiwan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 153. Australia Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 154. Australia Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 155. Australia Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 159. Europe Refractory Multiple Myeloma Treatment, by Country USD Million (2025-2030)
  • Table 160. Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 161. Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 162. Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 163. Germany Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 164. Germany Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 165. Germany Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 166. France Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 167. France Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 168. France Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 169. Italy Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 170. Italy Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 171. Italy Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 172. United Kingdom Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 174. United Kingdom Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 175. Netherlands Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 176. Netherlands Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 177. Netherlands Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 178. Rest of Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 180. Rest of Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 181. MEA Refractory Multiple Myeloma Treatment, by Country USD Million (2025-2030)
  • Table 182. MEA Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 183. MEA Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 184. MEA Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 185. Middle East Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 186. Middle East Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 187. Middle East Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 188. Africa Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 189. Africa Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 190. Africa Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 191. North America Refractory Multiple Myeloma Treatment, by Country USD Million (2025-2030)
  • Table 192. North America Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 193. North America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 194. North America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 195. United States Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 196. United States Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 197. United States Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 198. Canada Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 199. Canada Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 200. Canada Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 201. Mexico Refractory Multiple Myeloma Treatment, by Type USD Million (2025-2030)
  • Table 202. Mexico Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 203. Mexico Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Refractory Multiple Myeloma Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Refractory Multiple Myeloma Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Refractory Multiple Myeloma Treatment: by Drug Class USD Million (2018-2023)
  • Figure 7. South America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 8. Asia Pacific Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 9. Europe Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 10. MEA Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 11. North America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 12. Global Refractory Multiple Myeloma Treatment share by Players 2023 (%)
  • Figure 13. Global Refractory Multiple Myeloma Treatment share by Players (Top 3) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 16. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 23. Bristol Myers Squibb Company (Unite States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol Myers Squibb Company (Unite States) Revenue: by Geography 2023
  • Figure 25. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 27. ONO PHARMACEUTICAL CO., LTD. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. ONO PHARMACEUTICAL CO., LTD. (Japan) Revenue: by Geography 2023
  • Figure 29. Global Refractory Multiple Myeloma Treatment: by Type USD Million (2025-2030)
  • Figure 30. Global Refractory Multiple Myeloma Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 31. Global Refractory Multiple Myeloma Treatment: by Drug Class USD Million (2025-2030)
  • Figure 32. South America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 33. Asia Pacific Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 34. Europe Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 35. MEA Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 36. North America Refractory Multiple Myeloma Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Takeda Pharmaceutical Company Limited (Japan)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (Unite States)
  • Amgen Inc. (United States)
  • ONO PHARMACEUTICAL CO., LTD. (Japan)
Additional players considered in the study are as follows:
Janssen Pharmaceuticals, Inc. (United States) , AbbVie Inc (United States) , Sanofi (France)
Select User Access Type

Key Highlights of Report


Jan 2024 239 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Refractory Multiple Myeloma Treatment Market Quantitative research analysis
Global Refractory Multiple Myeloma Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (Unite States), Amgen Inc. (United States) and ONO PHARMACEUTICAL CO., LTD. (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing use of online platforms and social media to reach wider audiences and educate patients and healthcare professionals." is seen as one of major influencing trends for Refractory Multiple Myeloma Treatment Market during projected period 2023-2030.
The Refractory Multiple Myeloma Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Refractory Multiple Myeloma Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Hypermetropia Treatment Comprehensive Study by Type (Prescription, Surgery), End-User (Hospitals, Specialty Centres, Diagnostic Centres, Clinics, Others), Laser Procedure Types (Photorefractive Kerat...
$ 3650
Canine Leptospirosis Comprehensive Study by Drug (Doxycycline, Penicillin, Ampicillin, Pfizerpen), Route of Administration (Oral, Intravenous), Distribution Channel (Veterinary hospital pharmacies, V...
$ 3450
Graves Disease Comprehensive Study by Type (Anti-Thyroid Drugs, Lodine and Iodides, Radioactive Lodine, Lonic Inhibitors), Application (Hospital, Specialty Clinics), Distribution Channel (Hospital Di...
$ 3450
Dystrophic Epidermolysis Bullosa Treatment Comprehensive Study by Therapy (Gene therapy, Bone Marrow (Stem Cell) Transplantation, Protein Replacement Therapies, Cell-based Therapies), Treatment (Anti...
$ 3750
Cutaneous T-cell Lymphomas (CTCL) Comprehensive Study by Type (Mycosis Fungoides (MF), Sezary Syndrome (SS), Others), Treatment (Radiation Therapy, Chemotherapy, Immunotherapy, Targeted therapy, Othe...
$ 3500
Lichen Nitidus Treatment Comprehensive Study by Type (Corticosteroids, Retinoid, Antihistamines, Phototherapy), Route of Administration (Topical, Oral), Diagnosis (Electrocardiogram, Electrophysiolog...
$ 3450